All In Biotech

Drug Trial Radar · NCT07900568

Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HXN-1013 Following Subcutaneous Administration in Healthy Participants and Participants With Mild-to-Moderate Asthma

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Feb 15, 2028

Study completion May 30, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.

Conditions

  • Health Adults
  • Asthma

Interventions

  • HXN-1013Drug

    Participants will receive a single subcutaneous dose of HXN-1013.

  • PlaceboDrug

    Participants will receive a single subcutaneous dose of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Up to day 141

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Bayswater, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.